Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Maladaptive role of neutrophil extracellular traps in pathogen-induced lung injury
Emma Lefrançais, … , Carolyn S. Calfee, Mark R. Looney
Emma Lefrançais, … , Carolyn S. Calfee, Mark R. Looney
Published February 8, 2018
Citation Information: JCI Insight. 2018;3(3):e98178. https://doi.org/10.1172/jci.insight.98178.
View: Text | PDF
Research Article Immunology Pulmonology

Maladaptive role of neutrophil extracellular traps in pathogen-induced lung injury

  • Text
  • PDF
Abstract

Neutrophils dominate the early immune response in pathogen-induced acute lung injury, but efforts to harness their responses have not led to therapeutic advancements. Neutrophil extracellular traps (NETs) have been proposed as an innate defense mechanism responsible for pathogen clearance, but there are concerns that NETs may induce collateral damage to host tissues. Here, we detected NETs in abundance in mouse models of severe bacterial pneumonia/acute lung injury and in human subjects with acute respiratory distress syndrome (ARDS) from pneumonia or sepsis. Decreasing NETs reduced lung injury and improved survival after DNase I treatment or with partial protein arginine deiminase 4 deficiency (PAD4+/–). Complete PAD4 deficiency (PAD4–/–) reduced NETs and lung injury but was counterbalanced by increased bacterial load and inflammation. Importantly, we discovered that the lipoxin pathway could be a potent modulator of NET formation, and that mice deficient in the lipoxin receptor (Fpr2–/–) produced excess NETs leading to increased lung injury and mortality. Lastly, we observed in humans that increased plasma NETs were associated with ARDS severity and mortality, and lower plasma DNase I levels were associated with the development of sepsis-induced ARDS. We conclude that a critical balance of NETs is necessary to prevent lung injury and to maintain microbial control, which has important therapeutic implications.

Authors

Emma Lefrançais, Beñat Mallavia, Hanjing Zhuo, Carolyn S. Calfee, Mark R. Looney

×

Figure 4

Degradation of NETs with DNase I reduces lung injury and improves survival.

Options: View larger image (or click on image) Download as PowerPoint
Degradation of NETs with DNase I reduces lung injury and improves surviv...
(A–H) WT mice were challenged with methicillin-resistant Staphylococcus aureus (MRSA; 5 × 107 CFU, i.t.) and treated 2 hours later with DNase I (2,000 units, i.t.) to disrupt neutrophil extracellular traps (NETs). Bronchoalveolar lavage (BAL), blood, and lung tissue were collected 8 hours after infection. (B) BAL NETs (neutrophil elastase–DNA complexes), (C) BAL WBC, (D) BAL albumin concentration, (E) lung vascular permeability to albumin, (F) excess lung water, (G) bacterial counts in blood, and (H) BAL bacterial counts were quantified. (I and J) Survival experiment schema and curves for mice challenged with MRSA (5 × 107 CFU, i.t.) and treated with DNase I or diluent control (i.t.) at 2, 10, 18, and 28 hours after infection (n = 24). (K–N) Mice were challenged with MRSA (7 × 107 CFU, i.t.) and treated with vancomycin (150 mg/kg, i.p.) and DNase I (2,000–4,000 units, i.t.) or diluent control at 2, 10, 18, and 28 hours after infection (n = 10). (M) Body temperature loss and (N) blood lactate 24 hours after infection. (J and L) Survival curves were compared using Gehan-Breslow-Wilcoxon test. (B–H, M, N) Data were analyzed using Student’s t test (n = 3–10). *P ≤ 0.05,**P ≤ 0.01. ns, not significant.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts